Phase I Trial of Induction Dasatinib Therapy in Patients with Resectable Malignant Pleural Mesothelioma.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Dasatinib (Primary)
- Indications Mesothelioma
- Focus Biomarker; Therapeutic Use
- 25 Sep 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 26 Feb 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018 as reported by ClinicalTrials.gov record.
- 25 Feb 2015 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov record.